Thrilled to share that I have joined Perspective Therapeutics as SVP, Business Development! Perspective is pioneering alpha-emitting Pb212 radiopharmaceuticals enabling the visualization, targeting and treatment of tumors, with the potential to improve efficacy and minimize toxicity.#radiopharmaceuticals #Pb212

- Established and led Albireo’s business development function as first BD hire - Executed seven partnerships for Albireo’s lead asset, Bylvay®, to maximize its global value. Led partnering discussions for early-stage pipeline assets- Sourced and evaluated >50 companies across APAC as prospective partners for Bylvay and defined critical success factors for regulatory approval and commercialization in region- Supported key corporate initiatives (e.g., corporate valuation model, corporate strategy, financings) and part of M&A term

Business Development • Defined and implemented BD strategy and negotiated licenses and collaborations with multiple organizations for cell therapy division of Intellia as part of founding team• Led licensing negotiations for multiple novel technologies to augment genome editing platform; negotiated and executed numerous MTAs • Developed BD strategy, including identifying and pitching to target companies, synthesizing partnering materials and delivering conference presentations Alliance Management (Head of Intellia’s Alliance Management function from April 2018 onwards)• Led Alliance Management team (one direct report): managed high-profile, cross-functional, scientific collaborations including with Novartis and Regeneron• Renegotiated agreement with Novartis to provide additional non-dilutive funding and expanded technology access rights for Intellia • Implemented codevelopment / copromotion agreement with Regeneron• Represented BD/AM on program team for Intellia’s lead asset, directing the team to meet requirements of contract, and led negotiations on contractual issues

• Led out-licensing of ARIAD’s marketed asset (Iclusig®) and late-stage clinical asset (brigatinib), including regional and worldwide partnerships encompassing a broad range of deal structures • Identified and evaluated potential partners in different regions; acted as key contact throughout negotiations• Structured deal terms and created supporting financial analyses; negotiated term sheets and final partnering agreements • Presented business case assessments to company leadership in support of partnering strategy • As sole BD representative reporting to CBO, responsible for developing de novo in-licensing business development strategy and processes

• Identified novel licensing opportunities in oncology and adjacent therapeutic areas via extensive database screens and attendance at major partnering meetings• Evaluated 100+ oncology partnering opportunities and made recommendations based on scientific and commercial merit • Led large, cross-functional diligence teams: developed project plans, drove team consensus, and presented recommendations to C-level management • Collaborated with functional leads on technical analysis by reviewing of scientific data and leading KOL interviews • Determined deal financials via benchmarking analysis and valuation models (with Finance) • Negotiated term sheets and took part in definitive agreement discussions in coordination with Business Legal and IP attorneys

Life sciences strategy consulting across multiple therapeutic areas for biopharma, medtech, and diagnostics companiesProjects included:- Acquisition screens for licensing and M&A opportunities - Revenue forecasts and valuations- M&A due diligence- Growth and market entry strategies - Diagnostics strategy

Life sciences management consulting for biopharma companies, VCs, and government agenciesProjects included: - Technical and commercial due diligence- Process redesign and change management

Supported the Tech Transfer Department's business development and licensing activities through assessment and marketing of intellectual property

Molecular biology researchProfessional Certificate: Biotechnology Business and Marketing (UC Berkeley Extension)